CoChat
Sign Up
Cited by 25Cancer-related molecular mechanisms researchOvarian cancer diagnosis and treatmentMicroRNA in disease regulation

Elevated LINC00909 Promotes Tumor Progression of Ovarian Cancer via Regulating the miR‐23b‐3p/MRC2 Axis

Open access
Yang, Xu, Wu, Guixia, Yang, Fan, He, Lang, Xie, Xiaohui, Li, Lan, Yang, Lei, Ma, Yulan +9 more·2021·Oxidative Medicine and Cellular Longevity
DOI 10.1155/2021/5574130PMC PMC8318762
Open this paper in CoChat — free accountOpen PDF

Abstract

Ovarian cancer (OC), the third common gynecologic malignancy, contributes to the most cancer‐caused mortality in women. However, 70% of patients with OC are diagnosed at an advanced stage, of which the 5‐year survival is less than 30%. Long noncoding RNAs (long ncRNAs or lncRNA), a type of RNA with exceeding 200 nucleotides in length but no protein‐coding capability, have been demonstrated to involve the pathogenesis of various cancers and show considerable potential in the diagnosis of OC. In this study, we found that the LINC00909 expression in tumor and serum specimens of OC patients was elevated, determined by real‐time quantitative, and droplet digital PCR. In receiver operating characteristic (ROC) analysis, our results revealed that serum LINC00909 distinguished cancers from normal ovarian tissue with 87.8% of sensitivity and 69.6% of specificity (AUC, 81.2%) and distinguished serous ovarian cancer from normal ovarian tissue with 90.0% of sensitivity and 75.9% of specificity (AUC, 84.5%). Furthermore, we observed that the tumor and serum LINC00909 level was positively associated with the International Federation of Gynecology and Obstetrics (FIGO) stage and the Eastern Cooperative Oncology Group (ECOG) score (reflecting patients’ performance status). Also, patients with low serum LINC00909 level showed a longer overall (hazard ratio, HR = 1.874, p = 0.0004) and progression‐free (HR = 1.656, p = 0.0017) survival. Functional assays indicated that the elevation of LINC00909 expression contributes to cell proliferation, migration, and invasion capability of ovarian cancer cells. Besides, we demonstrated that LINC00909 functions as a competing endogenous RNA (ceRNA) of MRC2 mRNA by sponging miR‐23‐3p, and thereby promotes epithelial‐to‐mesenchymal transition (EMT) of ovarian cancer cells. Therefore, we highlight that the LINC00909/miR‐23b‐3p/MRC2 axis is implicated in the pathogenesis of ovarian cancer, and serum LINC00909 may be a promising biomarker for the diagnosis of OC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2021/5574130

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • lncRNA LINC00909 is upregulated in tumor and serum tissues and adsorbs miR-23a-3p, promoting epithelial-mesenchymal transition in ovarian cancer cells.

    “The lncRNA LINC00909 is upregulated in the tumor and serum tissues and adsorbs miR-23a-3p, thereby promoting epithelial-mesenchymal transition (EMT) in OC cells”

    From Recent advances of miR-23 in human diseases and growth development (2025) · cites this paper as [87]

    The Introduction and Discussion report elevated LINC00909 in ovarian tumor and serum specimens and say it promotes EMT by sponging miR-23b-3p. The claim names miR-23a-3p instead; our copy does not support that target. (LLM, conf=0.92)

    Experimental — accuracy not yet measured

  • Decline of miR-23a-3p is crucial to the pathogenesis of ovarian cancer.

    “the decline of miR-23a-3p is crucial to the pathogenesis of OC.”

    From Recent advances of miR-23 in human diseases and growth development (2025) · cites this paper as [87]

    The Results (§3.5) identify miR-23b-3p, not miR-23a-3p, as a functional mediator in ovarian cancer. A search for miR-23a-3p found no passage in our copy addressing whether its decline contributes to ovarian cancer pathogenesis; the finding about miR-23b-3p does not rule that out. (LLM, conf=0.78)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 43

  1. [1]Javadi S. Ganeshan D. M. Qayyum A. Iyer R. B. Bhosale P. Ovarian cancer, the revised FIGO staging system, and the role of imaging AJR. American Journal of Roentgenology 2016 206 6 1351 1360 10.2214/AJR.15.15199 2-s2.0-84999287109 27042752 · DOI
  2. [2]Reavis H. D. Drapkin R. The tubal epigenome - an emerging target for ovarian cancer Pharmacology & Therapeutics 2020 210 p. 107524 10.1016/j.pharmthera.2020.107524 PMC7237289 32197795 · DOI
  3. [3]Arend R. Martinez A. Szul T. Birrer M. J. Biomarkers in ovarian cancer: to be or not to be Cancer 2019 125 Suppl 24 4563 4572 10.1002/cncr.32595 31967683 · DOI
  4. [4]Jayson G. C. Kohn E. C. Kitchener H. C. Ledermann J. A. Ovarian cancer The Lancet 2014 384 9951 1376 1388 10.1016/S0140-6736(13)62146-7 2-s2.0-84908173579 24767708 · DOI
  5. [5]Mutch D. G. Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer Gynecologic Oncology 2014 133 3 401 404 10.1016/j.ygyno.2014.04.013 2-s2.0-84901631423 24878391 · DOI
  6. [6]Cho K. R. Shih I. M. Ovarian cancer Annual Review of Pathology 2009 4 1 287 313 10.1146/annurev.pathol.4.110807.092246 2-s2.0-66149083645 18842102 PMC2679364 · DOI
  7. [7]Mirza M. R. Coleman R. L. González-Martín A. The forefront of ovarian cancer therapy: update on PARP inhibitors Annals of Oncology 2020 31 9 1148 1159 10.1016/j.annonc.2020.06.004 32569725 · DOI
  8. [8]Gil N. Ulitsky I. Regulation of gene expression by _cis_ -acting long non-coding RNAs Nature Reviews. Genetics 2020 21 2 102 117 10.1038/s41576-019-0184-5 31729473 · DOI
  9. [9]Cui L. Xie X. Y. Wang H. Chen X. L. Liu S. L. Hu L. N. Expression of long non-coding RNA HOTAIR mRNA in ovarian cancer Sichuan Da Xue Xue Bao Yi Xue Ban 2013 44 1 57 59 23600210
  10. [10]Peng Y. Tang D. Zhao M. Kajiyama H. Kikkawa F. Kondo Y. Long non-coding RNA: a recently accentuated molecule in chemoresistance in cancer Cancer Metastasis Reviews 2020 39 3 825 835 10.1007/s10555-020-09910-w 32594276 · DOI
  11. [11]Bhan A. Soleimani M. Mandal S. S. Long noncoding RNA and cancer: a new paradigm Cancer Research 2017 77 15 3965 3981 10.1158/0008-5472.CAN-16-2634 2-s2.0-85026737045 28701486 PMC8330958 · DOI
  12. [12]Sanchez Calle A. Kawamura Y. Yamamoto Y. Takeshita F. Ochiya T. Emerging roles of long non-coding RNA in cancer Cancer Science 2018 109 7 2093 2100 10.1111/cas.13642 2-s2.0-85049328919 29774630 PMC6029823 · DOI
  13. [13]Schmitt A. M. Chang H. Y. Long noncoding RNAs in cancer pathways Cancer Cell 2016 29 4 452 463 10.1016/j.ccell.2016.03.010 2-s2.0-84962739336 27070700 PMC4831138 · DOI
  14. [14]Moore J. B. Uchida S. Functional characterization of long noncoding RNAs Current Opinion in Cardiology 2020 35 3 199 206 10.1097/HCO.0000000000000725 32068613 PMC7236552 · DOI
  15. [15]Tripathi M. K. Doxtater K. Keramatnia F. Role of lncRNAs in ovarian cancer: defining new biomarkers for therapeutic purposes Drug Discovery Today 2018 23 9 1635 1643 10.1016/j.drudis.2018.04.010 2-s2.0-85046702417 29698834 PMC6139057 · DOI
  16. [16]Huang Z. Zhou J. K. Peng Y. He W. Huang C. The role of long noncoding RNAs in hepatocellular carcinoma Molecular Cancer 2020 19 1 p. 77 10.1186/s12943-020-01188-4 32295598 PMC7161154 · DOI
  17. [17]Chan J. J. Tay Y. Noncoding RNA:RNA regulatory networks in cancer International Journal of Molecular Sciences 2018 19 5, article 1310 10.3390/ijms19051310 2-s2.0-85046300969 PMC5983611 29702599 · DOI
  18. [18]Chi Y. Wang D. Wang J. Yu W. Yang J. Long non-coding RNA in the pathogenesis of cancers Cell 2019 8 9, article 1015 10.3390/cells8091015 31480503 PMC6770362 · DOI
  19. [19]Fang Y. Fullwood M. J. Roles, functions, and mechanisms of long non-coding RNAs in cancer Genomics, Proteomics & Bioinformatics 2016 14 1 42 54 10.1016/j.gpb.2015.09.006 2-s2.0-84960115390 26883671 PMC4792843 · DOI
  20. [20]Kopp F. Mendell J. T. Functional classification and experimental dissection of long noncoding RNAs Cell 2018 172 3 393 407 10.1016/j.cell.2018.01.011 2-s2.0-85041930461 29373828 PMC5978744 · DOI
  21. [21]Chen S. Wu D. D. Sang X. B. The lncRNA HULC functions as an oncogene by targeting ATG7 and ITGB1 in epithelial ovarian carcinoma Cell Death & Disease 2017 8 10, article e3118 10.1038/cddis.2017.486 2-s2.0-85031281476 29022892 PMC5682654 · DOI
  22. [22]Wang H. Fang L. Jiang J. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation Cell Death & Disease 2018 9 11 p. 1103 10.1038/s41419-018-1148-y 2-s2.0-85055613200 30375398 PMC6207559 · DOI
  23. [23]Yousefi H. Maheronnaghsh M. Molaei F. Long noncoding RNAs and exosomal lncRNAs: classification, and mechanisms in breast cancer metastasis and drug resistance Oncogene 2020 39 5 953 974 10.1038/s41388-019-1040-y 31601996 · DOI
  24. [24]Choudhari R. Sedano M. J. Harrison A. L. Long noncoding RNAs in cancer: from discovery to therapeutic targets Advances in Clinical Chemistry 2020 95 105 147 10.1016/bs.acc.2019.08.003 32122521 · DOI
  25. [25]Misawa A. Takayama K. I. Inoue S. Long non-coding RNAs and prostate cancer Cancer Science 2017 108 11 2107 2114 10.1111/cas.13352 2-s2.0-85028828340 28796922 PMC5665759 · DOI
  26. [26]Peng W. X. Koirala P. Mo Y. Y. LncRNA-mediated regulation of cell signaling in cancer Oncogene 2017 36 41 5661 5667 10.1038/onc.2017.184 2-s2.0-85029581103 28604750 PMC6450570 · DOI
  27. [27]Zhang J. le T. D. Liu L. Li J. Inferring and analyzing module-specific lncRNA-mRNA causal regulatory networks in human cancer Briefings in Bioinformatics 2019 20 4 1403 1419 10.1093/bib/bby008 2-s2.0-85072988811 29401217 · DOI
  28. [28]Liang H. Yu T. Han Y. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression Molecular Cancer 2018 17 1 p. 119 10.1186/s12943-018-0870-5 2-s2.0-85054936426 30098599 PMC6087007 · DOI
  29. [29]Wu D. D. Chen X. Sun K. X. Wang L. L. Chen S. Zhao Y. Role of the lncRNA ABHD11-AS1 in the tumorigenesis and progression of epithelial ovarian cancer through targeted regulation of RhoC Molecular Cancer 2017 16 1 p. 138 10.1186/s12943-017-0709-5 2-s2.0-85027510472 28818073 PMC5561620 · DOI
  30. [30]Azam F. Latif M. F. Farooq A. Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals Case Reports in Oncology 2019 12 3 728 736 10.1159/000503095 2-s2.0-85072784957 31616281 PMC6792426 · DOI · Paper page
  31. [31]Li J.-H. Liu S. Zhou H. Qu L. H. Yang J. H. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data Nucleic Acids Research 2014 42 D1 D92 D97 10.1093/nar/gkt1248 2-s2.0-84891818924 24297251 PMC3964941 · DOI
  32. [32]Hu Y. P. Jin Y. P. Wu X. S. LncRNA-HGBC stabilized by HuR promotes gallbladder cancer progression by regulating miR-502-3p/SET/AKT axis Molecular Cancer 2019 18 1 p. 167 10.1186/s12943-019-1097-9 31752906 PMC6868746 · DOI
  33. [33]Wang Y. Yang L. Chen T. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis Molecular Cancer 2019 18 1 p. 28 10.1186/s12943-019-0957-7 2-s2.0-85061853228 30782188 PMC6381672 · DOI
  34. [34]Liang Y. Song X. Li Y. LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis Molecular Cancer 2020 19 1 p. 85 10.1186/s12943-020-01206-5 32384893 PMC7206728 · DOI
  35. [35]Sturge J. Wienke D. Isacke C. M. Endosomes generate localized Rho-ROCK-MLC2-based contractile signals via Endo180 to promote adhesion disassembly The Journal of Cell Biology 2006 175 2 337 347 10.1083/jcb.200602125 2-s2.0-33750337537 17043135 PMC2064574 · DOI
  36. [36]Wienke D. Davies G. C. Johnson D. A. The collagen receptor Endo180 (CD280) is expressed on basal-like breast tumor cells and promotes tumor growth in vivo Cancer Research 2007 67 21 10230 10240 10.1158/0008-5472.CAN-06-3496 2-s2.0-35948956254 17974964 · DOI
  37. [37]Gokulnath P. de Cristofaro T. Manipur I. Long non-coding RNA MAGI2-AS3 is a new player with a tumor suppressive role in high grade serous ovarian carcinoma Cancers 2019 11 12 p. 2008 10.3390/cancers11122008 31842477 PMC6966615 · DOI
  38. [38]Calanca N. Rainho C. A. Abildgaard C. Rogatto S. R. The interplay between long noncoding RNAs and proteins of the epigenetic machinery in ovarian cancer Cancers 2020 12 9 p. 2701 10.3390/cancers12092701 32967233 PMC7563210 · DOI
  39. [39]Martini P. Paracchini L. Caratti G. lncRNAs as novel indicators of patients' prognosis in stage I epithelial ovarian cancer: a retrospective and multicentric study Clinical Cancer Research 2017 23 9 2356 2366 10.1158/1078-0432.CCR-16-1402 2-s2.0-85019068090 27827314 · DOI
  40. [40]Qiu J. J. Lin Y. Y. Ye L. C. Overexpression of long non-coding RNA HOTAIR predicts poor patient prognosis and promotes tumor metastasis in epithelial ovarian cancer Gynecologic Oncology 2014 134 1 121 128 10.1016/j.ygyno.2014.03.556 2-s2.0-84903124951 24662839 · DOI
  41. [41]Liu Z. Lu C. Hu H. LINC00909 promotes tumor progression in human glioma through regulation of miR-194/MUC1-C axis Biomedicine & Pharmacotherapy 2019 116 p. 108965 10.1016/j.biopha.2019.108965 2-s2.0-85066022545 31132669 · DOI
  42. [42]Ma L. Wang Y. Y. Jiang P. LncRNA LINC00909 promotes cell proliferation and metastasis in pediatric acute myeloid leukemia via miR-625-mediated modulation of Wnt/β-catenin signaling Biochemical and Biophysical Research Communications 2020 527 3 654 661 10.1016/j.bbrc.2020.05.001 32423818 · DOI
  43. [43]Kogianni G. Walker M. M. Waxman J. Sturge J. Endo180 expression with cofunctional partners MT1-MMP and uPAR-uPA is correlated with prostate cancer progression European Journal of Cancer 2009 45 4 685 693 10.1016/j.ejca.2008.11.023 2-s2.0-60349083291 19112015 · DOI

Cited by

Sorted by citations

Authors
Yang, X., Wu, G., Yang, F., He, L., Xie, X., Li, L., Yang, L., Ma, Y., Zhang, Q., Chen, J., Zou, S., Han, Q., Wang, Y., Liu, S., Li, J., Han, B., & Liu, K.
Affiliations
  • Xinjiang Medical University (CN)
  • Chengdu Fifth People's Hospital (CN)
  • Guangzhou Women and Children Medical Center (CN)
  • Shanghai Jiao Tong University (CN)
Corresponding author
Liu, KaiJiang
ORCID
Venue
Oxidative Medicine and Cellular Longevity
Publisher
Wiley
Published
2021-01
Volume
2021
Issue
1
Pages
5574130-5574130
ISSN
  • 1942-0994 (ISSN-L)
  • 1942-0900
DOI
10.1155/2021/5574130
PMC
PMC8318762
OpenAlex
W3184422142
Cited by
25
References
0
Citations by year
2026: 1 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 8 · 2021: 2
FWCI
1.99
Type
journal article
Language
en
Open access
Licence
Locations
  • Oxidative Medicine and Cellular Longevity (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
Keywords
long non-coding RNA, ovarian cancer, miR-23b-3p, MRC2, competing endogenous RNA, epithelial-mesenchymal transition, tumor progression, serum biomarkers, prognostic factors, cell proliferation, migration and invasion, serous ovarian cancer, cell cycle regulation
MeSH terms
Adult, Aged, Aged, 80 and over, Female, Humans, Middle Aged, Ovarian Neoplasms, Disease Progression, MicroRNAs, Young Adult, RNA, Long Noncoding

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review